CY1110205T1 - Ανοσογονος συνθεση και μεθοδοι - Google Patents

Ανοσογονος συνθεση και μεθοδοι

Info

Publication number
CY1110205T1
CY1110205T1 CY20101100663T CY101100663T CY1110205T1 CY 1110205 T1 CY1110205 T1 CY 1110205T1 CY 20101100663 T CY20101100663 T CY 20101100663T CY 101100663 T CY101100663 T CY 101100663T CY 1110205 T1 CY1110205 T1 CY 1110205T1
Authority
CY
Cyprus
Prior art keywords
subject
composition
methods
expression
direct
Prior art date
Application number
CY20101100663T
Other languages
English (en)
Inventor
John H Eldridge
Zimra R Israel
Michael A Egan
Stephen A Udem
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04722764A external-priority patent/EP1605971B1/en
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1110205T1 publication Critical patent/CY1110205T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Μία μέθοδος επαγωγής μιας αντίγονο ειδικής απόκρισης σε ένα άτομο θηλαστικού περιλαμβάνει τα στάδια χορήγησης στο άτομο μιας αποτελεσματικής ποσότητας μιας πρώτης σύνθεσης που περιλαμβάνει ένα DNA πλασμίδιο που περιέχει μία DNA αλληλουχία η οποία κωδικεύει ένα αντιγόνο υπό τον έλεγχο ρυθμιστικών αλληλουχιών που κατευθύνουν την έκφραση αυτής σε ένα κύτταρο θηλαστικού ή σπονδυλωτού. Η μέθοδος περιλαμβάνει επίσης την χορήγηση στο άτομο μιας δεύτερης σύνθεσης η οποία περιλαμβάνει έναν ανασυνδυασμένο ιό θυλακιώδους στοματίτιδας (VSV) που περιέχει μία αλληλουχία νουκλεϊνικού οξέος η οποία κωδικεύει το αντιγόνο υπό τον έλεγχο ρυθμιστικών αλληλουχιών που κατευθύνουν την έκφραση αυτής σε ένα κύτταρο θηλαστικού ή σπονδυλωτού. Ο rVSV είναι σε μία υλοποίηση ικανός για αναδιπλασιασμό. Τα κιτ για χρήση σε ανοσοποιητικές και θεραπευτικές αγωγές της νόσου περιλαμβάνουν τα συστατικά και τις μεθόδους για την πρακτική εφαρμογή αυτής της μεθόδου.
CY20101100663T 2003-03-26 2010-07-15 Ανοσογονος συνθεση και μεθοδοι CY1110205T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45787603P 2003-03-26 2003-03-26
US54673304P 2004-02-23 2004-02-23
EP04722764A EP1605971B1 (en) 2003-03-26 2004-03-23 Immunogenic composition and methods

Publications (1)

Publication Number Publication Date
CY1110205T1 true CY1110205T1 (el) 2015-01-14

Family

ID=33313369

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100663T CY1110205T1 (el) 2003-03-26 2010-07-15 Ανοσογονος συνθεση και μεθοδοι

Country Status (7)

Country Link
JP (1) JP5635950B2 (el)
KR (1) KR101059721B1 (el)
CN (1) CN102085377B (el)
CY (1) CY1110205T1 (el)
DE (1) DE602004027359D1 (el)
ES (1) ES2345198T3 (el)
PT (1) PT1605971E (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662885A (zh) * 2020-06-22 2020-09-15 扬州大学 两株基因组高度同源猪繁殖与呼吸综合征病毒强弱毒株感染性克隆构建、拯救与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus
PL1605971T3 (pl) * 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby

Also Published As

Publication number Publication date
JP5635950B2 (ja) 2014-12-03
DE602004027359D1 (de) 2010-07-08
JP2011251979A (ja) 2011-12-15
CN102085377A (zh) 2011-06-08
PT1605971E (pt) 2010-07-29
ES2345198T3 (es) 2010-09-17
KR101059721B1 (ko) 2011-08-29
KR20060002872A (ko) 2006-01-09
CN102085377B (zh) 2014-03-12

Similar Documents

Publication Publication Date Title
BRPI0408779A (pt) uso de composições, composição imunogênica e kit
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
DE68924162D1 (de) Stressproteine und verwendungen dafür.
BR9907691A (pt) Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
ES2185762T3 (es) Vacunas contra la peste.
DE60044665D1 (de) Her2/neu fusionsproteine
EA202090759A3 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
DA’Dara et al. A DNA‐prime/protein‐boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection
MX2011012807A (es) Composiciones y metodos para administracion de vacunas contra virus del dengue.
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
ATE547529T1 (de) Materialien und verfahren im zusammenhang mit verbesserten impfstrategien
ES2196032T3 (es) Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican.
Dai et al. DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
CY1110205T1 (el) Ανοσογονος συνθεση και μεθοδοι
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
Touihri et al. Design of different strategies of multivalent DNA-based vaccination against rabies and canine distemper in mice and dogs
AR022662A1 (es) Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407